ALK-Abelló

ALK B · Nasdaq Copenhagen · Denmark

Public Market Listing

ALK BNasdaq Copenhagen

Nasdaq Copenhagen primary exchange listing

Live quotes, historical charts, and market capitalization for ALK-Abelló are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Alpha- and beta-adrenergic receptors (agonist)Small molecule
Allergic Conditions
Anaphylaxis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Epinephrine · neffyPhase 2Urticaria Chronic
Est. primary completion 2027-06 · NCT06927999 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.